Seeking Alpha

Shadow Play's  Instablog

Shadow Play
Send Message
I am just an ordinary investor looking out for family,friends and others at the same time. I try to invest in stocks that will pay me back handsomely for holding for long periods of time. I've been trading for twelve years and have achieved many goals in life by simply keeping it simple and that... More
  • Following Up On Antares' Vibex MTX 0 comments
    Dec 13, 2012 5:32 PM | about stocks: ATRS

    As a quick follow up from my last article,Vibex MTX has took a new direction. The Medi-jet MTX has a new name and that name is OTREXUP. The CEO of Antares (ATRS), Paul Wotton, has just said that they are going to have multiple uses for the new self injected drug. The original business model was for arthritis patients but they have now decided that there is another market for this product and that is for psoriasis treatment. There are over seven million psoriasis sufferers in the United States alone and the number continues to climb. Antares seems to think that their new self injected device will fit that growing market as well

    Filing for FDA approval for the new OTREXUP will be in three weeks, which should be the first week of January 2013. Remember, management first said this past Summer that the NDA filing would be sometime in the first half of 2013 and then recently changed it to Q1 of 2013. Now they have bumped up the NDA filling for the first week of the new year. You do not have to light a fire under this management as they seem excited and very willing to get this product out on the market. After just listening to the web call at the Oppenheimer Healthcare Conference, I can understand why. Antares will be the first and only company in the Untied States with a self administered product that treats RA patients with a device using the subcutaneous method, or SC MTX for short. This new news should be welcomed by investors being that the OTREXUP self injected device has blockbuster potential and will be on the market no later than Q1 of 2014. But again, do not let the date fool you. Management has constantly bumped up their timeline and I would be shocked if this product is not on the market come Q4 of 2013. I can say this because Antares is gearing up and have already hired 30 plus sales reps to accommodate the 3000 rheumetologist that are lined up to use this method of treatment for arthritis and psoriasis patients.

    Also, it is worth noting, Antares is in search of a partner for International use of their OTREXUP product. I would think,after listening for the demanding need here in the States, it should not be hard to find one.

    Disclosure: I am long ATRS.

    Stocks: ATRS
Back To Shadow Play's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • $ATRS started as a buy by Jefferies
    Dec 19, 2012
  • I see $ATRS meditating from the 3.60's-4.10's until late January. Once the Vibex MTX filing comes to light with FDA, then it pushes to $5.
    Dec 11, 2012
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.